foxo4 dri senolytic 10mg Vial - Buy Online FOXO4-DRI: A Breakthrough Peptide Targeting
FOXO4 DRI: A Breakthrough Peptide Targeting Aging at Its Roots PARTICLE, s. r. o. FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity.
Pay in 4 interest-free payments of $5.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


